In conclusion, this prospective study provides insights into the predictive role of early changes in IL-10 and TNF-α after the first Ate/Bev treatment for clinical outcomes following Ate/Bev treatment in advanced HCC patients. The gene discussed is IL10; the disease is hepatocellular carcinoma.